TS
AEON icon

Thomas Steyer’s AEON Biopharma AEON Stock Holding History

Thomas Steyer’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,083
Closed -$1.51M – 195
2022
Q4 		$1.51M Hold
2,083
– – 0.01% 169
2022
Q3 		$1.48M Hold
2,083
– – 0.01% 211
2022
Q2 		$1.47M Hold
2,083
– – 0.01% 211
2022
Q1 		$1.47M Hold
2,083
– – 0.01% 215
2021
Q4 		$1.46M Hold
2,083
– – 0.01% 212
2021
Q3 		$1.46M Hold
2,083
– – 0.01% 216
2021
Q2 		$1.45M Buy
+2,083
New +$1.46M 0.01% 215

Other funds holding AEON

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $129M AUM 16.02% 1-Year Est. Return

Thomas Steyer's AEON Position: Q1 2023 in Review

Thomas Steyer sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 2,083 shares — an estimated $1.51M sold.

Thomas Steyer first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $1.51M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Thomas Steyer reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Thomas Steyer sold 2,083 AEON Biopharma shares in Q1 2023, an estimated $1.51M.
  • Thomas Steyer first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
  • Thomas Steyer's AEON Biopharma position peaked at $1.51M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Farallon Capital Management's 13F filing for Q1 2023, filed 15 May 2023.